Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization DOI
Runmin Cao,

Yurun Zhang,

Ling Cao

et al.

European Journal of Gastroenterology & Hepatology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 5, 2025

Aim: This study aimed to investigate the relationship between lung function and metabolic dysfunction–associated steatotic liver disease (MASLD), potential mediating role of type 2 diabetes. Methods Data from 2007 2012 National Health Nutrition Examination Survey were used. Logistic regression analysis was employed assess association parameters [forced vital capacity (FVC), forced expiratory volume in 1 s (FEV ), FEV /FVC] MASLD prevalence while exploring diabetes mediation. Further analyses included linkage disequilibrium score regression, Mendelian randomization, meta-analysis examine causal MASLD, considering Results The results showed that higher FVC levels associated with decreased risk, partially this relationship. Genetic supported a link acting as an intermediary. However, no significant found /FVC MASLD. Conclusion identified playing partial role.

Language: Английский

Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank DOI Creative Commons
Tae Seop Lim, Sujin Kwon,

Sung A. Bae

et al.

Journal of Cachexia Sarcopenia and Muscle, Journal Year: 2025, Volume and Issue: 16(2)

Published: March 4, 2025

Language: Английский

Citations

1
Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression DOI Creative Commons
Sumin Oh, Yang Hyun Baek, Sung‐Ju Jung

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(2), P. 247 - 262

Published: Jan. 29, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by fat accumulation in the liver. MASLD encompasses both steatosis and MASH. Since MASH can lead to cirrhosis cancer, must be distinguished during patient treatment. Here, we investigate genomes, epigenomes, transcriptomes of patients identify signature gene set for more accurate tracking progression.

Language: Английский

Citations

8
Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study DOI Creative Commons
Yewan Park, Jooyi Jung, Seungbong Han

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 20, 2024

Summary Background The new nomenclature of metabolic dysfunction‐associated steatotic liver disease (MASLD) substituting nonalcoholic fatty was proposed along with a category MASLD increased alcohol intake (MetALD). Aims We aimed to explore the cancer risk by and MetALD. Methods This nationwide cohort study included 3,596,709 participants who underwent health check‐up in 2011 South Korea. Steatotic (SLD) defined as index ≥30. Participants were categorized into four exclusive groups: MASLD, MetALD, other combination aetiology no SLD. subdistribution hazard ratio (SHR) calculated using Fine–Gray model after adjusting variables. Results During 33.9 million person‐years follow‐up, 285,845 (7.9%) developed cancers. Compared SLD, MetALD had an all cancer. Liver escalated from SLD (SHR, 1.16; 95% CI, 1.12–1.21), 2.06; 1.92–2.20) 8.16; 7.69–8.67). Gastrointestinal cancers including oesophagus, stomach, colorectal, biliary pancreas 1.13; 1.11–1.15), 1.17; 1.14–1.21) 1.09; 1.05–1.13). A modest increase lung hormone‐sensitive observed MASLD. Conclusions showed that are associated cancer, particularly gastrointestinal findings build evidence for clinical outcomes while highlighting importance managing properly

Language: Английский

Citations

7
Comparison of NAFLD, MAFLD And MASLD Prevalence And Clinical Characteristics in Asia Adults DOI
Xinjuan Huang,

Ruoling Yu,

Xinyun Tan

et al.

Journal of Clinical and Experimental Hepatology, Journal Year: 2024, Volume and Issue: 15(1), P. 102420 - 102420

Published: Oct. 8, 2024

Language: Английский

Citations

7
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials DOI Creative Commons
Ming‐Lun Yeh, Ming‐Lung Yu

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 29(4), P. 969 - 972

Published: Sept. 18, 2023

Language: Английский

Citations

13
Impacts of cardiometabolic risk factors and alcohol consumption on all-cause mortality among MASLD and its subgroups DOI
Mengqi Li, Wenya Chen, You Deng

et al.

Nutrition Metabolism and Cardiovascular Diseases, Journal Year: 2024, Volume and Issue: 34(9), P. 2085 - 2094

Published: May 22, 2024

Language: Английский

Citations

5
Emerging mechanisms of non-alcoholic steatohepatitis and novel drug therapies DOI
Hao Chen, Yang Zhou, Haiping Hao

et al.

Chinese Journal of Natural Medicines, Journal Year: 2024, Volume and Issue: 22(8), P. 724 - 745

Published: Aug. 1, 2024

Language: Английский

Citations

5
Changing from NAFLD to MASLD: Similar cumulative incidence of reflux esophagitis between NAFLD and MASLD DOI Creative Commons
Shuhei Fukunaga,

Michita Mukasa,

Dan Nakano

et al.

Clinical and Molecular Hepatology, Journal Year: 2023, Volume and Issue: 30(1), P. 121 - 123

Published: Jan. 1, 2023

Language: Английский

Citations

11
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study DOI Creative Commons
Gi‐Ae Kim, Seogsong Jeong, Heejoon Jang

et al.

Liver Cancer, Journal Year: 2023, Volume and Issue: 13(4), P. 426 - 437

Published: Dec. 22, 2023

<b><i>Introduction:</i></b> This study aimed to investigate the liver-related outcomes of newly suggested metabolic dysfunction-associated steatotic liver disease (MASLD) and MASLD with increased alcohol intake (MetALD), as well alcohol-associated (ALD). <b><i>Methods:</i></b> From a National Health Insurance Service Screening Cohort, we included 369,094 participants who underwent health checkups between 2009 2010 in South Korea. Steatotic (SLD) was defined fatty index ≥60. The risk primary cancer (PLCa), hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), incident cirrhosis, decompensated cirrhosis compared no SLD. subdistribution hazard ratio (SHR) calculated using Fine-Gray model regarding competing risks. <b><i>Results:</i></b> A total 3,232 (0.9%) developed PLCa during median follow-up 3,227,176 person-years: 0.5% SLD, 1.1% MASLD, 1.3% MetALD, 1.9% ALD. Competing analysis revealed that (SHR: 1.65; 95% CI: 1.44−1.88), MetALD 1.87; 1.52−2.29), ALD 1.86; 1.39−2.49) were associated an PLCa. 1.96; 1.67−2.31), 2.23; 1.75−2.84), 2.34; 1.67−3.29) higher HCC. No significant difference observed iCCA. order <b><i>Conclusion:</i></b> have PLCa, HCC, but not These findings may serve robust ground for prognostic value MetALD.

Language: Английский

Citations

11
Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease DOI Creative Commons
Yue Wang,

Sherlot Juan Song,

Yichong Jiang

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: June 27, 2024

In managing metabolic dysfunction-associated steatotic liver disease, which affects over 30% of the general population, effective noninvasive biomarkers for assessing disease severity, monitoring progression, predicting development liver-related complications, and treatment response are crucial.The advantage simple fibrosis scores lies in their widespread accessibility through routinely performed blood tests extensive validation different clinical settings.They have shown reasonable accuracy diagnosing advanced good performance excluding majority patients with a low risk complications.Among elevated serum scores, more specific imaging biomarker has proved useful to accurately identify at biomarkers, enhanced is most widely utilized been approved United States as prognostic biomarker.For availability vibration-controlled transient elastography largely improved past years, enabling use stiffness measurement (LSM) accurate assessment significant fibrosis, cirrhosis.Combining LSM other available enhances ability diagnose at-risk steatohepatitis; predict some reaching an comparable that biopsy.Magnetic resonance imaging-based modalities provide quantification though current utilization limited research settings.Expanding future practice depends on factors such cost facility availability.

Language: Английский

Citations

4